Pay in 4 interest-free payments of $6.45 Learn more
Ships within 48 hours · Estimated delivery Aug 20 - Aug 25
Canadians spend enormous amounts on diabetes medications, cardiovascular treatments, and joint surgeries that effective weight management could prevent or delay
Efpeglenatide Efpeglenatide is a novel, long-acting GLP-1 receptor agonist developed by Hanmi Pharmaceuticals (South Korea) utilizing the proprietary LAPSCOVERY (Long-Acting Protein/Peptide Discovery) technology platform
Compounded Liraglutide is a daily medication, unlike many GLP-1 medications that are taken weekly
In Phase 2 trials published in the *New England Journal of Medicine* (2023), participants lost an average of 17.5% of body weight at the highest dose over 24 weeks outperforming tirzepatide and semaglutide in head-to-head data comparisons
If the vial was at temperatures above 86 degrees F for any significant period (more than a few hours): the risk of meaningful degradation is high
